Stock Market Reviews

Read and share opinions on ANRO (Alto Neuroscience, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year?
  Nov 14, 2025
• Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
  Nov 12, 2025
• How Much Upside is Left in Alto Neuroscience, Inc. (ANRO)? Wall Street Analysts Think 61.99%
  Nov 10, 2025
• Alto Neuroscience to Participate in Upcoming Investor Conferences
  Oct 28, 2025
• Here's Why Alto Neuroscience, Inc. (ANRO) is a Great Momentum Stock to Buy
  Oct 23, 2025
• Can Alto Neuroscience, Inc. (ANRO) Climb 27.45% to Reach the Level Wall Street Analysts Expect?
  Oct 23, 2025
• Alto Neuroscience Announces $50 Million Private Placement Financing
  Oct 20, 2025
• Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
  Oct 20, 2025
• Alto Neuroscience Receives FDA Fast Track Designation for Drug Candidate ALTO-101 for Cognitive Impairment in Schizophrenia
  Oct 17, 2025
• Alto Neuroscience (ANRO): Evaluating Valuation After FDA Fast Track Milestone for Lead Schizophrenia Candidate
  Oct 6, 2025
• Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
  Oct 3, 2025
• Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia
  Sep 9, 2025
• Alto Neuroscience’s Depression Drug Shows Positive Biomarker Results in Phase 2 Trial
  Aug 20, 2025
• Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights
  Aug 13, 2025
• Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors
  Aug 13, 2025